Dx dialogues: identifying patients who might benefit from an LAI for schizophrenia
Ragy Girgis, MD, explains which patients might benefit the most from using an LAI to treat their schizophrenia.
Up Next
Dx dialogues: stigma surrounding LAI use for schizophrenia and the importance of patient education
Dx dialogues: pharmacologic advances for the treatment and management of schizophrenia
Dx dialogues: why early intervention is critical in managing tardive dyskinesia
Dx dialogues: the challenges of treating tardive dyskinesia the "old-fashioned way"
Dx dialogues: considerations when deciding whether to initiate pharmacologic interventions for patients with AD
Dx dialogues: VMAT2 inhibitors and future treatments for tardive dyskinesia
Dx dialogues: novel approaches in development for the treatment of AD
Caring for patients with schizophrenia and other psychiatric disorders
A caregiver's guide to schizophrenia medications
Dx dialogues: recent advancements and implementation strategies in opioid use disorder treatment
